Infinity Pharmaceuticals (NASDAQ:INFI) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI – Free Report) in a research report sent to investors on Saturday. The firm issued a hold rating on the biotechnology company’s stock. Infinity Pharmaceuticals Stock Performance Infinity Pharmaceuticals has a 1 year low of $0.01 and a 1 year high of $0.01. The stock’s 50-day […]

Related Keywords

Adeleneq Perkins , ,Charles Schwab Investment Management Inc ,Goldman Sachs Group Inc ,Infinity Pharmaceuticals Stock Performance ,Infinity Pharmaceuticals ,Infinity Pharmaceuticals Inc ,Millennium Management ,Infinity Pharmaceuticals Company Profile ,News Ratings For Infinity Pharmaceuticals Daily ,Hedge Funds Weigh In On Infinity Pharmaceuticals ,Free Report ,Get Free Report ,Director Adelene ,Street Corp ,Schwab Investment Management ,Goldman Sachs Group ,Sachs Group ,Infinity Pharmaceuticals Daily ,Nasdaq Infi ,Infi ,Medical ,45665g30 ,Initiated Coverage ,Stocknews Com ,